Faculty Profile

Andrew Wiznia, MDAndrew Wiznia, MD
Phone: 718-918-4664
E-mail: andrew.wiznia@nbhn.net

Dr. Wiznia is the Director of the Division of Allergy and Immunology. He is the Director of both the pediatric and adult HIV services at Jacobi. Dr. Wiznia is also the Medical Director of the Division of Research at Jacobi and the co-chair of the New York City HHC Research Committee. Dr. Wiznia has served on numerous state-wide and national HIV committees, and is on the writing committee for the “Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.” Dr. Wiznia is a Professor of Pediatrics at the Albert Einstein College of Medicine.

Undergraduate School:

Brandeis University

Medical School:

College of Physicians and Surgeons of Columbia Uni

Training:

  • Internship and Residency: Bronx Municipal Hospital Center (now Jacobi Medical Center)
  • Chief Residency: Bronx-Lebanon Hospital Center
  • Allergy/Immunology Fellowship: Albert Einstein College of Medicine

Bibliography:

  • Larson KB, Cressey TR, Wiznia A, et al; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team. Pharmacokinetics of once-daily darunavir/ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults. J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7.
  • Foca M, Yogev R, Wiznia A, et al; IMPAACT P1058A Team. Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults. Pediatr Infect Dis J. 2016 May 16.
  • Cressey TR, Yogev R, Wiznia A, et al; IMPAACT P1058A Team. Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults. J Pediatric Infect Dis Soc. 2016 Apr 21.
  • Weintraub A, Mellins CA, Wiznia A, et al. Patterns and correlates of serostatus disclosure to sexual partners by perinatally-infected adolescents and young adults. AIDS Behav. 2016 Feb 13.
  • Nachman S, Alvero C, Wiznia A, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83.
  • Viani RM, Alvero C, Wiznia A, et al; P1093 Study Team. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced hiv-1 infected adolescents: forty-eight-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015 Nov;34(11):1207-13.
  • Fairlie L, Karalius B, Wiznia A, et al; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT). CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. AIDS. 2015 Oct 23;29(16):2109-19.
  • Dehority W, Abadi J, Wiznia A, Viani RM. Use of integrase inhibitors in HIV-infected children and adolescents. Drugs. 2015 Sep;75(13):1483-97.
  • Rizk ML, Du L, Bennetto-Hood C, Wiznia A, et al. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. J Clin Pharmacol. 2015 Jul;55(7):748-56
  • Evans SD, Mellins CA, Wiznia A, et al. HIV treatment adherence measurement and reporting concordance in youth with perinatally acquired HIV infection and their caregivers. AIDS Patient Care STDS. 2015 Jan;29(1):43-51.
  • Krogstad P, Patel K, Wiznia A, et al. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents. AIDS. 2015 Mar 27;29(6):683-93.
  • Rizk ML, Du L, Bennetto-Hood C, Wiznia A, et al. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. J Clin Pharmacol. 2015 Jul;55(7):748-56.
  • Gromadzka O, Santamaria EK, Wiznia A, et al. sexual health knowledge in a sample of perinatally hiv-infected and perinatally-exposed uninfected youth. J HIV AIDS Soc Serv. 2015 Jul 1;14(3):277-293.
  • Evans SD, Mellins CA, Wiznia A, et al. HIV treatment adherence measurement and reporting concordance in youth with perinatally acquired HIV infection and their caregivers. AIDS Patient Care STDS. 2015 Jan;29(1):43-51.
  • de Mulder M, York VA, Wiznia A, Rosenberg MG, et al. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. HIV Med. 2014 Mar;15(3):135-43.
  • Nachman S, Zheng N, Wiznia A, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014 Feb;58(3):413-22..
  • Neely M, Rutstein R, Wiznia A, et al. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013 Sep;32(9):e370-6.
  • de Vos G, Nazari R, Wiznia A, et al. Discordance between aeroallergen specific serum IgE and skin testing in children younger than 4 years. Ann Allergy Asthma Immunol. 2013 Jun;110(6):438-43.
  • Champiat S, Garrison KE, Wiznia A, et al: T cells target APOBEC3 proteins in human immunodeficiency virus type1-infected humans and simian immunodeficiency virus-infected indian rhesus macaques. J Virol 2013 Jun;87(11):6073-80.